Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer (STOP-HCC)
The safety and effectiveness of TheraSphere will be evaluated in patients with unresectable hepatocellular carcinoma in whom treatment with standard-of-care sorafenib is planned. All patients receive the standard-of-care sorafenib with or without the addition of TheraSphere.